Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Greenberger

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
AEM Education and Training|July 25, 2020
Changes to the ACGME Common Program Requirements and Their Potential Impact on Emergency Medicine Core Faculty Protected TimeSarah M Greenberger, John T Finnell, Bernard P Chang, et al.
Journal of Medicinal Chemistry|September 1, 2000
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitorsA Wissner, D M Berger, D H Boschelli, et al.
Molecular Pharmacology|November 3, 2007
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumorsStuart L Emanuel, Terry V Hughes, Mary Adams, et al.
Leukemia|August 17, 2011
Endogenous knockdown of survivin improves chemotherapeutic response in ALL modelsD J Morrison, L E Hogan, G Condos, et al.
Cancer Research|April 19, 2003
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivoFrank Loganzo, Carolyn M Discafani, Tami Annable, et al.
Journal of Medicinal Chemistry|May 18, 2001
Design, synthesis, and preclinical characterization of novel, highly selective indole estrogensC P Miller, M D Collini, B D Tran, et al.
Journal of Medicinal Chemistry|September 3, 2004
Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286)Arie Zask, Gary Birnberg, Katherine Cheung, et al.
Journal of Medicinal Chemistry|December 28, 2002
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)Allan Wissner, Elsebe Overbeek, Marvin F Reich, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2008
Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinasesGuozhang Xu, Lily Lee Searle, Terry V Hughes, et al.
Life Science Alliance|August 5, 2025
Epigenetic liquid biopsies reveal endothelial turnover and erythropoiesis in asymptomatic COVID-19Roni Ben-Ami, Netanel Loyfer, Eden Cohen, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
AEM Education and Training|July 25, 2020
Changes to the ACGME Common Program Requirements and Their Potential Impact on Emergency Medicine Core Faculty Protected TimeSarah M Greenberger, John T Finnell, Bernard P Chang, et al.
Journal of Medicinal Chemistry|September 1, 2000
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitorsA Wissner, D M Berger, D H Boschelli, et al.
Molecular Pharmacology|November 3, 2007
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumorsStuart L Emanuel, Terry V Hughes, Mary Adams, et al.
Leukemia|August 17, 2011
Endogenous knockdown of survivin improves chemotherapeutic response in ALL modelsD J Morrison, L E Hogan, G Condos, et al.
Cancer Research|April 19, 2003
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivoFrank Loganzo, Carolyn M Discafani, Tami Annable, et al.
Journal of Medicinal Chemistry|May 18, 2001
Design, synthesis, and preclinical characterization of novel, highly selective indole estrogensC P Miller, M D Collini, B D Tran, et al.
Journal of Medicinal Chemistry|September 3, 2004
Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286)Arie Zask, Gary Birnberg, Katherine Cheung, et al.
Journal of Medicinal Chemistry|December 28, 2002
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)Allan Wissner, Elsebe Overbeek, Marvin F Reich, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2008
Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinasesGuozhang Xu, Lily Lee Searle, Terry V Hughes, et al.
Life Science Alliance|August 5, 2025
Epigenetic liquid biopsies reveal endothelial turnover and erythropoiesis in asymptomatic COVID-19Roni Ben-Ami, Netanel Loyfer, Eden Cohen, et al.
Pageof 10